SELENBP1 and breast cancer: MCF-7, a human breast cancer cell line, and MCF-7/MX, a multidrug resistant variant which overexpresses BCRP, were used in this study to assess the cytotoxicity of MTO in the MCF/MX cells and MDR reversal of MTO.